Fulgent Genetics Files 8-K Report

Ticker: FLGT · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1674930

Fulgent Genetics, Inc. 8-K Filing Summary
FieldDetail
CompanyFulgent Genetics, Inc. (FLGT)
Form Type8-K
Filed DateOct 20, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, filing

TL;DR

Fulgent Genetics filed an 8-K on 10/20/25. Standard disclosure, no major news yet.

AI Summary

On October 20, 2025, Fulgent Genetics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating a routine update or disclosure without specifying any new material events or financial figures in the provided text.

Why It Matters

This 8-K filing from Fulgent Genetics, Inc. serves as a public record of significant company events or financial updates, important for investors to monitor.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events, financial data, or forward-looking statements that would indicate a change in risk.

Key Players & Entities

  • Fulgent Genetics, Inc. (company) — Registrant
  • October 20, 2025 (date) — Date of earliest event reported
  • 4399 Santa Anita Avenue El Monte, California 91731 (address) — Principal Executive Offices
  • 626-350-0537 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing?

The filing is for "Other Events" and "Financial Statements and Exhibits," suggesting a routine disclosure or update.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is October 20, 2025.

What is the principal executive office address for Fulgent Genetics, Inc.?

The principal executive office is located at 4399 Santa Anita Avenue, El Monte, California 91731.

What is Fulgent Genetics, Inc.'s telephone number?

The registrant's telephone number, including area code, is (626) 350-0537.

What is the SIC code for Fulgent Genetics, Inc.?

The Standard Industrial Classification (SIC) code is 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.

Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-10-20 06:04:52

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share FLGT The Nasdaq Stock Mar

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 20, 2025, Fulgent Genetics, Inc. (the "Company") issued a press release announcing preliminary clinical data from the ongoing phase 2 trial of FID-007 in combination with cetuximab in 2 nd line treatment in patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). A copy of the Company's press release containing this information is filed as Exhibit 99.1 to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 20, 2025 FULGENT GENETICS, INC. By: /s/ Paul Kim Name: Paul Kim Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.